G

GemPharmatech Co Ltd
SSE:688046

Watchlist Manager
GemPharmatech Co Ltd
SSE:688046
Watchlist
Price: 13.53 CNY -1.24% Market Closed
Market Cap: 5.5B CNY
Have any thoughts about
GemPharmatech Co Ltd?
Write Note

GemPharmatech Co Ltd
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

GemPharmatech Co Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
G
GemPharmatech Co Ltd
SSE:688046
Accrued Liabilities
ÂĄ44.8m
CAGR 3-Years
27%
CAGR 5-Years
55%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Accrued Liabilities
ÂĄ2.2B
CAGR 3-Years
17%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Accrued Liabilities
ÂĄ732.6m
CAGR 3-Years
18%
CAGR 5-Years
30%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Accrued Liabilities
ÂĄ393.2m
CAGR 3-Years
-1%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Accrued Liabilities
ÂĄ346m
CAGR 3-Years
25%
CAGR 5-Years
28%
CAGR 10-Years
46%
W
WuXi XDC Cayman Inc
HKEX:2268
Accrued Liabilities
ÂĄ74.9m
CAGR 3-Years
109%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GemPharmatech Co Ltd
Glance View

Market Cap
5.5B CNY
Industry
Life Sciences Tools & Services

GemPharmatech Co., Ltd. engages in research and development, manufacture, and sale of experimental mouse models. The company is headquartered in Nanjing, Jiangsu and currently employs 1,342 full-time employees. The company went IPO on 2022-04-25. The firm uses gene-editing and other technologies to produce mouse models. The firm also involves in the business of customized model breeding, drug efficacy analysis, and model customization. The Company’s products are mainly used to satisfy the experimental demands in the fields of gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental researches.

Intrinsic Value
21.04 CNY
Undervaluation 36%
Intrinsic Value
Price
G

See Also

What is GemPharmatech Co Ltd's Accrued Liabilities?
Accrued Liabilities
44.8m CNY

Based on the financial report for Dec 31, 2023, GemPharmatech Co Ltd's Accrued Liabilities amounts to 44.8m CNY.

What is GemPharmatech Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
55%

Over the last year, the Accrued Liabilities growth was 4%. The average annual Accrued Liabilities growth rates for GemPharmatech Co Ltd have been 27% over the past three years , 55% over the past five years .

Back to Top